# A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures

> **NCT07233239** · PHASE1 · RECRUITING · sponsor: **Jazz Pharmaceuticals** · enrollment: 100 (estimated)

## Conditions studied

- Focal Seizures

## Interventions

- **DRUG:** CBD-OS

## Key facts

- **NCT ID:** NCT07233239
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-26
- **Primary completion:** 2027-11-29
- **Final completion:** 2027-11-29
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07233239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07233239, "A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT07233239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*